Nivolumab + Ipilimumab

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Osteosarcoma

Conditions

Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Melanoma, Hepatoblastoma, Hepatocellular Carcinoma, Neuroblastoma, Wilms Tumor

Trial Timeline

Feb 18, 2022 → Mar 12, 2024

NCT ID

NCT05302921

About Nivolumab + Ipilimumab

Nivolumab + Ipilimumab is a phase 2 stage product being developed by Bristol Myers Squibb for Osteosarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05302921. Target conditions include Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02186249	Pre-clinical	Completed	—	—	Malignant Melanoma
NCT07024862	Pre-clinical	Active	Oct 24, 2024	Jun 30, 2025	Metastatic Non-small Cell Lung Cancer
NCT06487156	Pre-clinical	Active	Oct 11, 2023	Oct 11, 2030	Non-small Cell Lung Cancer (NSCLC)
NCT05219435	Phase 2	Active	Jul 6, 2022	Dec 1, 2025	Urothelial Cancer
NCT05302921	Phase 2	Completed	Feb 18, 2022	Mar 12, 2024	Osteosarcoma
NCT05088889	Phase 1	UNKNOWN	Jan 25, 2022	Jul 1, 2024	Stage IV Pancreatic Cancer
NCT04966676	Phase 2	Terminated	Jan 24, 2022	Feb 19, 2025	Non Small Cell Lung Cancer
NCT05215470	Phase 2	Active	Jan 18, 2022	Nov 30, 2026	Renal Cancer Metastatic
NCT04465643	Phase 1	Completed	Jun 8, 2021	Jul 30, 2025	Nerve Sheath Tumors
NCT04938232	Phase 2	Active	Jun 4, 2021	Aug 1, 2026	Hodgkin Lymphoma
NCT04495010	Phase 2	Withdrawn	Mar 31, 2021	Oct 23, 2027	Melanoma
NCT04513522	Approved	Completed	Dec 17, 2020	Jan 4, 2024	Kidney Neoplasms
NCT04434560	Phase 2	Terminated	Nov 4, 2020	Jun 17, 2021	Brain Metastases, Adult
NCT04575922	Phase 2	UNKNOWN	Oct 5, 2020	Jun 1, 2024	Metastatic Microsatellite Stable Colorectal Cancer
NCT04340193	Phase 3	Completed	Sep 14, 2020	Dec 12, 2023	Cancer, Hepatocellular
NCT04088500	Phase 2	Terminated	Sep 3, 2020	Nov 15, 2021	Renal Cell Carcinoma
NCT04361162	Phase 2	Active	May 18, 2020	Oct 1, 2026	Pancreatic Cancer
NCT03873402	Phase 3	Active	Jun 21, 2019	Mar 11, 2027	Renal Cell Carcinoma
NCT03461952	Phase 2	Terminated	Mar 11, 2019	Feb 9, 2022	Advanced Solid Tumors
NCT03789110	Phase 2	Active	Mar 8, 2019	Feb 28, 2026	Breast Cancer

Competing Products

18 competing products in Osteosarcoma

See all competitors

Product	Company	Stage	Hype Score
Azenosertib + Gemcitabine	Zentalis Pharmaceuticals	Phase 1/2	33
Lenvatinib + Ifosfamide + Etoposide + Lenvatinib	Eisai	Phase 2	52
Pemetrexed	Eli Lilly	Phase 2	52
pemetrexed	Eli Lilly	Phase 2	52
Camrelizumab in Combination With Neoadjuvant Chemotherapy	Jiangsu Hengrui Medicine	Phase 2	52
Apatinib	Jiangsu Hengrui Medicine	Phase 2	52
Olaparib + Ceralasertib	AstraZeneca	Phase 2	52
Saracatinib + Placebo	AstraZeneca	Phase 2	52
robatumumab	Merck	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
pazopanib	Novartis	Phase 2	52
Avelumab	Pfizer	Phase 2	51
Nivolumab + Azacitidine	Bristol Myers Squibb	Phase 1	32
Cisplatin liposomal	Insmed	Phase 1/2	38
Cabozantinib	Ipsen	Phase 2	49
Sm-EDTMP	Jazz Pharmaceuticals	Phase 2	49
LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).	Lantheus Holdings	Phase 1/2	38
REOLYSIN®	Oncolytics Biotech	Phase 2	44

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved